Tag: Advanced solid tumors
Nuvation Bio receives FDA clearance for NUV-1511 IND in advanced solid tumors
In a significant stride for cancer treatment, Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company dedicated to addressing unmet needs in oncology, announced the U.S. ... Read More
Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More
Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. ... Read More
BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type ... Read More
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors
US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with ... Read More
Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety ... Read More
Compugen kickstarts phase 1 trial of cancer immunotherapy COM701
Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in ... Read More
Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors
Xencor has launched a phase 1 clinical trial of its bispecific antibody XmAb20717, which is being developed for the treatment of multiple advanced solid tumors. ... Read More